- Home
- DRIO vs CMMB Comparison
DRIO vs CMMB Comparison
Compare DRIO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRIO
- CMMB
- Stock Information
- Founded
- DRIO 2011
- CMMB 2004
- Country
- DRIO United States
- CMMB Israel
- Employees
- DRIO N/A
- CMMB N/A
- Industry
- DRIO Medical/Dental Instruments
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- DRIO Health Care
- CMMB Health Care
- Exchange
- DRIO Nasdaq
- CMMB Nasdaq
- Market Cap
- DRIO 21.9M
- CMMB 22.0M
- IPO Year
- DRIO N/A
- CMMB N/A
- Fundamental
- Price
- DRIO $7.11
- CMMB $3.03
- Analyst Decision
- DRIO Strong Buy
- CMMB Strong Buy
- Analyst Count
- DRIO 2
- CMMB 2
- Target Price
- DRIO $50.00
- CMMB $26.50
- AVG Volume (30 Days)
- DRIO 31.2K
- CMMB 143.6K
- Earning Date
- DRIO 11-06-2025
- CMMB 08-14-2025
- Dividend Yield
- DRIO N/A
- CMMB N/A
- EPS Growth
- DRIO N/A
- CMMB N/A
- EPS
- DRIO N/A
- CMMB N/A
- Revenue
- DRIO $27,148,000.00
- CMMB N/A
- Revenue This Year
- DRIO $0.74
- CMMB N/A
- Revenue Next Year
- DRIO $19.61
- CMMB N/A
- P/E Ratio
- DRIO N/A
- CMMB N/A
- Revenue Growth
- DRIO 41.79
- CMMB N/A
- 52 Week Low
- DRIO $7.02
- CMMB $2.96
- 52 Week High
- DRIO $31.00
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- DRIO 31.31
- CMMB 26.72
- Support Level
- DRIO $8.91
- CMMB $2.96
- Resistance Level
- DRIO $10.60
- CMMB $3.14
- Average True Range (ATR)
- DRIO 0.98
- CMMB 0.22
- MACD
- DRIO -0.19
- CMMB 0.01
- Stochastic Oscillator
- DRIO 1.61
- CMMB 8.09
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.